Comments
The US Food and Drug Administration (USFDA) has closed its observations on Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of Granules India Ltd in Chantilly, Virginia, USA.
The facility had undergone a pre-approval inspection audit by the regulator from June 21-25, 2021. The audit is a pre-approval inspection for three of its applications filed from this facility. The FDA issued two minor observations during the audit.
“The observations were responded to within the stipulated time, and the FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on July 20, 2021. This is the fifth US FDA audit for this facility” Priyanka Chigurupati, Executive Director, GPI, said in a release.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.